Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions | Zendy

Andrew R. Lewis | Zendy; Carlos A. Padula | Zendy; J. Mark McKinney | Zendy; Beau Toskich | Zendy

Open Access

Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions

Author(s) -

Andrew R. Lewis,

Carlos A. Padula,

J. Mark McKinney,

Beau Toskich

Publication year - 2019

Publication title -

seminars in interventional radiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.35

H-Index - 40

eISSN - 1098-8963

pISSN - 0739-9529

DOI - 10.1055/s-0039-1697641

Subject(s) - medicine , hepatocellular carcinoma , ablation , thermal ablation , ablation therapy , radiology , tumor ablation , ablative case , treatment modality , surgery , radiation therapy , cancer , prostate cancer

Thermal ablation is widely regarded as definitive therapy for early-stage hepatocellular carcinoma, but its efficacy decreases in tumors greater than 3 cm. Extensive clinical studies have supported improved outcomes provided through combining transarterial embolic therapy with ablation in the treatment of larger tumors. This article will provide a survey of the science and data for combination therapy in both thermal and nonthermal ablation modalities, as well as describe emerging applications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research